文献速递肺结节与肺癌

临床检测的I期非小细胞肺癌中非侵袭性癌症的比例评估

Assessing the extent of non-aggressive cancer in clinically detected stage I non-small cell lung cancer.
PubMed 文献 · Thorax · 2017-10-20

该研究基于SEER-Medicare登记数据,纳入2197例≥65岁、组织学确诊且未治疗的I期非小细胞肺癌(NSCLC)患者,通过累积肺癌特异性生存曲线斜率趋零估计非侵袭性癌症比例。总体非侵袭性癌症率为2.4%(95%CI 1.0%-3.8%),性别间无显著差异,不同肿瘤大小间亦无显著差异。结论提示临床诊断的早期NSCLC中非侵袭性癌症比例较低,多数应接受根治性治疗。

要点

  • 临床检测的I期NSCLC中非侵袭性癌症总体率仅2.4%。
  • 性别间非侵袭性癌症率无显著差异(p=0.84)。
  • 不同肿瘤大小间非侵袭性癌症率无显著差异。

核心结论

  • 临床检测的I期NSCLC中非侵袭性癌症比例较低,多数应接受根治性治疗。

研究设计与样本

  • 基于SEER-Medicare登记的人群回顾性研究,纳入2197例≥65岁、组织学确诊、未治疗的I期NSCLC患者。

主要发现

  • 总体非侵袭性癌症率为2.4%(95%CI 1.0%-3.8%)。
  • 女性非侵袭性癌症率为1.9%(95%CI 0.0%-4.9%),男性为2.4%(95%CI 0.7%-4.1%),p=0.84。
  • 肿瘤大小<15 mm、15-24 mm、25-34 mm、35-44 mm、≥45 mm的非侵袭性癌症率分别为10.2%(95%CI 0.0%-29.3%)、2.1%(95%CI 0.0%-9.2%)、4.9%(95%CI 0.0%-10.3%)、1.8%(95%CI 0.0%-5.2%)、0.0%(95%CI 0.0%-1.0%)。
  • 与<15 mm相比,15-24 mm(p=0.36)、25-34 mm(p=0.57)、35-44 mm(p=0.38)、>45 mm(p=0.30)的非侵袭性癌症率均无统计学显著差异。

关键数值与推荐

  • 非侵袭性癌症定义为调整竞争风险后累积肺癌特异性生存曲线斜率趋近于零时的长期存活者。

临床怎么用

  • 临床诊断的I期NSCLC应默认按根治性治疗策略管理。

局限性

  • 研究仅纳入≥65岁Medicare人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overdiagnosis among clinically detected lung cancers likely consists of cases that are non-aggressive and slowly progressive and will never disseminate, cause symptoms or be a threat to a subject's survival, even if untreated. In this study, we estimate the prevalence of non-aggressive lung cancers from a large, population-based cancer registry. METHODS: We identified individuals ≥65 years with histologically confirmed, untreated stage I non-small cell lung cancers (NSCLCs) from the Surveillance, Epidemiology, and End Results-Medicare registry. We estimated the rate of non-aggressive lung cancers by determining the point at which the cumulative lung cancer-specific survival curve no longer changed (ie, the slope approaches zero). At this point, there are no additional deaths due to progressive lung cancer observed among untreated patients after adjusting for deaths from competing risks (these long-term survivors can be considered 'non-aggressive cases). RESULTS: The overall rate of non-aggressive cancers among 2197 clinically detected cases of untreated stage I NSCLC was 2.4%, 95% CI: 1.0% to 3.8%. The rate of non-aggressive cancer was 1.9% (95% CI: 0.0% to 4.9%) for women and 2.4% (95% CI: 0.7% to 4.1%) for men (p=0.84). When stratifying by tumour size, non-aggressive cancer rates were 10.2% (95% CI: 0.0% to 29.3%), 2.1% (95% CI: 0.0% to 9.2%), 4.9% (95% CI: 0.0% to 10.3%), 1.8% (95% CI: 0.0% to 5.2%) and 0.0% (95% CI: 0.0% to 1.0%) for tumour sizes <15 mm, 15-24 mm, 25-34 mm, 35-44 mm and ≥45 mm, respectively. In comparison with the smallest tumour sizes (<15 mm), the rates of non-aggressive cancers were not statistically significantly different for tumour sizes 15-24 mm (p=0.36), 25-34 mm (p=0.57), 35-44 mm (p=0.38) and tumour sizes >45 mm (p=0.30). DISCUSSION: We found relatively low rates of non-aggressive cancers among clinically detected, stage I NSCLC regardless of sex or size. Our findings suggest that most clinically diagnosed early stage cancers should be treated with curative intent.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Kale MS, Sigel K, Mhango G, et al. Assessing the extent of non-aggressive cancer in clinically detected stage I non-small cell lung cancer. Thorax. 2017. PMID: 29054884. doi:10.1136/thoraxjnl-2017-210309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。